Abstract
In this review the Basic and Translational Science Assembly of the European Respiratory Society (ERS) provides an overview of the 2022 international conference highlights. We discuss the consequences of respiratory events from birth until old age regarding climate change-related alterations in air quality due to pollution caused by increased ozone, pollen, wildfires and fuel combustion as well as the increasing presence of microplastic and microfibres. Early life events such as the effect of hyperoxia in the context of bronchopulmonary dysplasia and crucial effects of the intrauterine environment in the context of preeclampsia were discussed. The Human Lung Cell Atlas (HLCA) was put forward as a new point of reference for healthy human lungs. The combination of single-cell RNA-sequencing and spatial data in the HLCA has enabled the discovery of new cell types/states, new niches and served as a platform that facilitates further investigation of mechanistic perturbations. The role of cell death modalities in regulating the onset and progression of chronic lung diseases and its potential as a therapeutic target was also discussed. Translational studies identified novel therapeutic targets and immunoregulatory mechanisms in asthma. Lastly, it was highlighted that the choice of regenerative therapeutic depends on disease severity, ranging from transplantation to cell therapies and regenerative pharmacology.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Sara Cuevas Ocaña was supported by an Action for Pulmonary Fibrosis award to support attendance at the European Respiratory Society International Congress 2022.
Conflict of interest: Sara Rolandsson Enes declares personal consulting fees from Swedish StromaBio AB outside the submitted work.
Conflict of interest: Carola Voss declares research funding and salary from the European Union's Horizon 2020 research and innovation program under grant agreement No 953183 (HARMLESS) and No 686098 SmartNanoTox); and non-financial interests in spin-off company “Infinite” from H2020 SmartNanoTox.
Conflict of interest: Lareb S. N. Dean reports being a postdoctoral research associate on a Biotechnology and Biological Sciences Research Council (BBSRC) David Phillips Fellowship (BB/V004573/1) and an NIHR Southampton Biomedical Research Centre (BRC) Senior Research Fellowship; and that they received a British Association for Lung Research Travel Award to the European Respiratory Society International Congress 2022.
Conflict of interest: Matthew Loxham reports a Biotechnology and Biological Sciences Research Council (BBSRC) David Phillips Fellowship (BB/V004573/1) and an NIHR Southampton Biomedical Research Centre (BRC) Senior Research Fellowship to fund research and salary for a fellow; as well as research and equipment grants (total ∼GBP13,000) from Asthma, Allergy, and Inflammation Research Charity (UK), in the 36 months prior to manuscript submission.
Conflict of interest: Catherine M. Greene declares research funding paid to their institution by the National Institutes of Health, Vertex and the Alpha-1 Foundation; and an honorarium from Insmed, all in the 36 months prior to manuscript submission; as well as support for travel and accommodation at the European Respiratory Society International Congress 2022.
Conflict of interest: Irene H. Heijink declares research funding from Boehringer Ingelheim and Roche, outside the submitted work.
Conflict of interest: Audrey Joannes declares research funding to their institution, and support for attending meetings and/or travel from AIR de Bretagne, in the 36 months prior to manuscript submission.
Conflict of interest: Anne M. van der Does declares an unpaid role as Secretary of European Respiratory Society Group 03.02 (Airway cell biology and immunopathology).
Conflict of interest: Darcy E. Wagner declares research grants from the Swedish Research Council, the European Research Council, Vinnova, the Alternatives Research and Development Foundation and the Knut and Alice Wallenberg Foundation; and support from AstraZeneca for attendance at the company's Science Day 2022 in Gothenburg; and receipt of electrospun membranes to their lab from Cellevate AB, all in the 36 months prior to manuscript submission; as well as patents relating to “De- and recellularization of whole organs” and “Microwave processing for calcium phosphate nanowhiskers”; personal stock investments in Merck, Pfizer, Thermofisher and Viatris; and an unpaid role as Secretary of European Respiratory Society Group 03.03 (Mechanisms of lung injury and repair).
Conflict of interest: All other authors declare no competing interests.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received October 22, 2022.
- Accepted December 29, 2022.
- Copyright ©The authors 2023
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org